May 19, 2009 (FinancialWire) — Simcere Pharmaceutical Group (NYSE: SCR) has appointed Peng Wang as its chief scientific officer.

Wang most recently served as VP of discovery biology at WuXi PharmaTech (NYSE: WX). Before that he was a research fellow at Schering-Plough’s (NYSE: SGP) research institute, where he worked for eighteen years.

In his new role, Wang will lead Simcere’s research team in developing new products and research projects. He will also participate in the strategic planning of the R&D department and manage domestic and international research collaborations.

Nanjing, China-based Simcere Pharmaceutical is a manufacturer and supplier of branded generic and original pharmaceuticals in China. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication.

Simcere concentrates its research and development efforts on the treatment of diseases such as cancer, strokes, orthopaedics and infectious diseases.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.